Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Short-Term Safety and Performance of a Wound Dressing Evaluation (POLTX_Fiber)

11. november 2026 oppdatert av: Sebastian Probst

A Post-market Clinical Follow-up Study to Describe the Short-term Safety, Performance and Usability of poltx_fiber in Chronic Wounds

You can paste the following into the **Brief Summary** field: POLTX_CIP_template_e_klinv-mep\_…

The goal of this study is to learn about the safety, wound healing, and ease of use of POLTX_Fiber, an absorbent wound dressing that forms a gel when it takes up wound fluid. The study will include approximately 60 adults receiving outpatient care in Switzerland. Participants will have wounds that have been present for at least four weeks and produce moderate to large amounts of fluid. These may include venous leg ulcers, diabetic foot ulcers, pressure ulcers, or ulcers with more than one cause.

The main questions are:

  • What health problems or dressing-related problems occur during the study?
  • How much does wound size change after 30 days of treatment?
  • Can POLTX_Fiber be removed completely in one piece?
  • How easy is the dressing to apply and remove, and how comfortable is it for patients?

Participants will receive either POLTX_Fiber or Suprasorb Liquacel Pro, another absorbent wound dressing. Dressing assignment will follow a predefined schedule rather than chance. Participants and their care teams will know which dressing is used. Results for each dressing group will be described separately.

Participants will:

  • Receive their assigned dressing for up to 30 days, with dressing changes as needed.
  • Continue usual care for the underlying cause of their wound.
  • Attend wound assessments at the start of treatment, weekly during treatment, and at weeks 8 and 12.
  • Have their wound measured and photographed and checked for signs of infection.
  • Rate pain during dressing changes and report how comfortable the dressing feels.

After the study treatment ends, participants will receive wound dressings prescribed by their care team. Each participant will take part for 12 weeks.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This investigator-initiated, multicentre, open-label, non-randomized post-market clinical follow-up study will characterize the short-term safety, clinical performance, and usability of POLTX_Fiber under routine outpatient wound-care conditions. POLTX_Fiber is a CE-marked absorbent gelling fibre dressing used according to the manufacturer's instructions for use.

Consecutive eligible patients will be enrolled at participating centres. Following confirmation of eligibility and written informed consent, participants will be allocated in a 1:1 ratio to POLTX_Fiber or Suprasorb Liquacel Pro using a predefined, non-randomized sequential allocation schedule implemented separately at each site in REDCap. Assignment will not depend on wound characteristics, clinical suitability, or investigator preference. The Suprasorb Liquacel Pro group will provide contextual information on outcomes observed with an established dressing.

Both groups will continue appropriate care for the underlying wound condition. Dressing changes will follow the applicable instructions for use and clinical needs. Changes in treatment or early discontinuation for clinical reasons will be documented, including their rationale.

Wound area will be measured using digital planimetry. Standardized wound photographs will support central review of wound healing, tissue composition, and the condition of the surrounding skin. Although participants and treating clinicians will know the assigned dressing, central wound-image assessors will remain unaware of treatment allocation. Safety surveillance will include adverse events, events considered related to the dressings, and device deficiencies throughout participation.

Analyses will be descriptive and exploratory. Outcomes will be summarized separately for each dressing group using appropriate descriptive statistics. Where informative, confidence intervals will describe the precision of estimates. No formal between-group hypothesis testing is planned, and the study is not designed to establish superiority, non-inferiority, or equivalence between the dressings. Missing data will not be imputed; available observations and missing assessments will be reported.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Canton of Geneva
      • Chêne-Bougeries, Canton of Geneva, Sveits, 1224
    • Canton of Vaud
      • Lausanne, Canton of Vaud, Sveits, 1002
        • Lausanne University Hospital
        • Ta kontakt med:
      • Yverdon-les-Bains, Canton of Vaud, Sveits, 1400
        • Instituions Hospital Du Nord Vaudois
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18 years or older.
  • Diagnosed chronic wound present for at least 4 weeks and no longer than 2 years, showing delayed healing despite standard care. Eligible wound types are venous leg ulcers, diabetic foot ulcers, pressure ulcers, and mixed-etiology ulcers.
  • Moderate to large amounts of wound fluid, assessed using standardized criteria.
  • Wound area between 2 cm² and 50 cm² after appropriate debridement, measured using digital planimetry or standardized wound tracing.
  • Ability and willingness to provide written informed consent and comply with study visits and procedures.

Exclusion Criteria:

  • Known allergy or hypersensitivity to any component of POLTX_Fiber or Suprasorb Liquacel Pro.
  • Clinically infected wound requiring systemic antibiotic treatment at baseline, according to International Working Group on the Diabetic Foot or European Wound Management Association definitions.
  • Necrotic tissue covering more than 25% of the wound bed or known malignant transformation of the wound.
  • Severe arterial insufficiency, defined as an ankle-brachial index below 0.5.
  • Pregnancy or breastfeeding.
  • Severe systemic illness that may interfere with wound healing or safety assessment, including end-stage renal failure, active cancer under chemotherapy, immunosuppression, or systemic corticosteroid use.
  • Participation in another interventional clinical study or use of an investigational dressing or device within the previous 30 days.
  • Cognitive impairment or psychiatric disorder preventing informed consent or compliance with study requirements.
  • Inability to attend scheduled follow-up visits or expected relocation during the 12-week study period.
  • Any condition or circumstance that, in the investigator's opinion, could compromise participant safety or the scientific integrity of the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: POLTX_Fiber arm

POLTX_Fiber, an absorbent gelling fiber dressing for moderate-high exudate chronic wounds

POLTX_Fiber is a CE-marked absorbent gelling fibre wound dressing. It absorbs wound fluid and forms a gel to maintain a moist wound environment. The dressing will be applied directly to the study wound according to the manufacturer's instructions for use for up to 30 days or until wound closure, whichever occurs first. Dressing changes will depend on wound fluid levels and clinical needs. Participants will continue standard care for the underlying wound condition.

Placebo komparator: Suprasorb® Liquacel Pro, CE-marked gelling fiber dressing

Suprasorb® Liquacel Pro arm

POLTX_Fiber is a CE-marked absorbent gelling fibre wound dressing. It absorbs wound fluid and forms a gel to maintain a moist wound environment. The dressing will be applied directly to the study wound according to the manufacturer's instructions for use for up to 30 days or until wound closure, whichever occurs first. Dressing changes will depend on wound fluid levels and clinical needs. Participants will continue standard care for the underlying wound condition.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of adverse events and device deficiencies
Tidsramme: 12 Weeks

Number and percentage of participants experiencing adverse events, including serious adverse events and events considered related to the study dressing. Events will be characterized by seriousness, severity, expectedness, relationship to the dressing, action taken, and clinical outcome. Device deficiencies, such as dressing fragmentation or fibres remaining in the wound, will also be recorded and summarized. Results will be reported separately for each dressing group.

12 Weeks
Percentage wound area reduction from baseline to Day 30
Tidsramme: Baseline to Day 30 (±1 day).

Percentage change in study wound area, measured using imitoWound digital planimetry. Percentage wound area reduction will be calculated as: [(baseline wound area - Day 30 wound area) / baseline wound area] × 100. Positive values indicate a reduction in wound size; negative values indicate an increase. Results will be summarized separately for each dressing group.

Baseline to Day 30 (±1 day).
Proportion of POLTX_Fiber dressing removals completed in one piece
Tidsramme: Baseline through Day 30 (±1 day).

At each assessed POLTX_Fiber dressing removal, the clinician will record whether the dressing was completely removed in one piece (yes/no). For each participant receiving POLTX_Fiber, the number of removals completed in one piece will be divided by the total number of assessed removals and expressed as a percentage. These participant-level percentages will be summarized descriptively. The number of assessed removals and missing assessments will also be reported.

Baseline through Day 30 (±1 day).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage wound area reduction at Weeks 1, 2, 3, 8 and 12
Tidsramme: 12 weeks

Percentage wound area reduction from baseline to each specified visit, measured using imitoWound digital planimetry. The percentage will be calculated as: [(baseline wound area - wound area at the assessment visit) / baseline wound area] × 100. Positive values indicate a reduction in wound size; negative values indicate an increase. Results will be summarized separately for each dressing group and visit.

12 weeks
Change in wound tissue composition
Tidsramme: 12 weeks

Change from baseline in the percentage of the wound area covered by epithelial tissue, granulation tissue, slough/fibrin, and necrotic tissue, assessed using imitoWound digital wound imaging. Each tissue type will be expressed as a percentage of the total wound area. Changes will be reported in percentage points and summarized separately for each dressing group and visit.

12 weeks
Change from baseline in the condition of the skin surrounding the wound
Tidsramme: 12 weeks

Condition of the skin surrounding the study wound, assessed using standardized digital wound images and documented as healthy, macerated (softened or damaged by excess moisture), or erythematous (red). Changes from the baseline category will be summarized descriptively, with the number and percentage of participants in each category reported separately for each dressing group and visit.

12 weeks
Local infection signs
Tidsramme: 12 weeks

Local infection signs will be assessed using the TILI, recording six indirect criteria and three direct criteria. Change from baseline in the number of indirect criteria present (range: 0-6; higher values indicate more signs of local infection) will be summarized. The number and percentage of participants meeting the TILI criteria for antimicrobial wound treatment-at least five indirect criteria or at least one direct criterion-will also be reported. Results will be summarized separately for each dressing group and visit. TILI supports clinical assessment and does not independently establish a diagnosis of wound infection.

12 weeks
Investigator assessment of dressing usability and handling
Tidsramme: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).

Usability and handling of POLTX_Fiber will be assessed using the French version of the Investigator Usability and Handling Questionnaire (IUHQ). Items assess ease of application, comfort during application, ease of removal, and overall satisfaction. Each item uses a five-point scale, with higher ratings indicating a more favourable assessment. Responses will be summarized separately for each item and visit. Dressing integrity upon removal is reported separately as a primary outcome.

Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
Pain intensity before and after dressing changes
Tidsramme: Baseline and Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).

Participants will rate pain intensity immediately before and after dressing changes using a 10-cm visual analogue scale, ranging from 0 (no pain) to 10 (worst pain imaginable). Higher scores indicate greater pain intensity. Scores before and after dressing changes will be summarized separately for each dressing group and visit.

Baseline and Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).
Change from baseline in wound exudate amount
Tidsramme: 12 weeks

Wound fluid (exudate) amount will be assessed before wound cleansing using the exudate amount item of the Bates-Jensen Wound Assessment Tool. Scores range from 1 (none) to 5 (large), with higher scores indicating more wound fluid. Changes from baseline and the number and percentage of participants in each category will be summarized separately for each dressing group and visit.

12 weeks
Change from baseline in wound exudate colour
Tidsramme: 12 weeks

Wound fluid (exudate) colour will be assessed by the investigator and categorized as serous (clear/amber), serosanguinous (pink), or purulent (opaque/yellow/green). Changes from the baseline category and the number and percentage of participants in each category will be summarized separately for each dressing group and visit.

12 weeks
Change from baseline in wound exudate odour
Tidsramme: 12 weeks

Wound fluid (exudate) odour will be assessed by the investigator and categorized as absent, faint, moderate, or strong. Changes from the baseline category and the number and percentage of participants in each category will be summarized separately for each dressing group and visit.

12 weeks
Frequency of dressing changes during the treatment period
Tidsramme: Baseline through Day 30 (±1 day).

The total number of scheduled and unscheduled dressing changes will be recorded for each participant during the treatment period. Participants will be categorized by dressing-change frequency as ≤2, 3-4, or ≥5 changes per week. Total dressing counts and frequency categories will be summarized separately for each dressing group.

Baseline through Day 30 (±1 day).
Patient-reported global tolerability of the dressing
Tidsramme: Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).

Participants will independently rate dressing tolerability using a three-point scale: 0 = no issues, 1 = moderate tolerability, and 2 = poor tolerability. Higher scores indicate poorer tolerability. The number and percentage of participants selecting each response will be summarized separately for each dressing group and visit.

Weeks 1, 2, 3 and 4 (end of treatment, Day 30 ±1 day).

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

31. oktober 2027

Studiet fullført (Antatt)

30. november 2027

Datoer for studieregistrering

Først innsendt

23. april 2026

Først innsendt som oppfylte QC-kriteriene

4. mai 2026

Først lagt ut (Faktiske)

8. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • POLTX_Fiber
  • Polaroid Therapeutics (Annen identifikator: Polaroid Therapeutics)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Raw data will be shared using Yareta (https://yareta.unige.ch/home) a Swiss research platform using the FAIR priniples

IPD-delingstidsramme

from 2028 until 2029

Tilgangskriterier for IPD-deling

all researchers

IPD-deling Støtteinformasjonstype

  • ANALYTIC_CODE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .